NCT02207465View on ClinicalTrials.gov

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Locally Advanced Unresectable Pancreatic Cancer Treated With ChemoradiotherapyBorderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy
Interventions
RADIATION

Radiotherapy

DRUG

Abraxane

Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane

Trial Locations (2)

19104

RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

19380

RECRUITING

Chester County Hospital, West Chester

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER